Merck KGaA projects much higher income for 2013; Biogen raises forecast; Shires settle suit over ADHD drug;

@FiercePharma: Trending at FiercePharma.com: European regulators tag 100-plus drugs with 'black triangle.' Article | Follow @FiercePharma

@EricPFierce: Ipsen warns of shortages of its orphan drug Increlex. Story | Follow @EricPFierce

> Germany's Merck KGaA CEO Karl-Ludwig Kley Friday reconfirmed the expectation that 2013 net income will increase significantly. Item

> Biogen Idec ($BIIB) raised its earnings projections for the year after its first quarter results bested expectations. Story

> Shire ($SHPG) has settled patent litigation with Actavis ($ACT), allowing it to sell a generic version of Shire's ADHD drug Intuniv. Story

> FDA would get the control over some compounding pharmacies that it wants under new legislation offered up Friday. Story

> The largest and most advanced study for a vaccine to prevent HIV infection was halted by the U.S. after an interim look at the data showed it was unlikely to help recipients. Story

Medical Device News

@FierceMedDev: FDA wants more data on Insuline's pump. Article | Follow @FierceMedDev

@MarkHFierce: Now this is just cool: Carnegie Mellon U. folks are developing med devices you would swallow and partially digest. More | Follow @MarkHFierce

 @DamianFierce: A spike in restructuring costs slashed Covidien's profits, despite a revenue jump. Story | Follow @DamianFierce

> Insuline pump hits FDA obstacle. Item

> Life Tech shareholder sues over $13.6B Thermo buyout. Report

> VC giant NEA backs Topera in $25M Series C. Article

Biotech News

@FierceBiotech: NIH stops HIV vaccine trial after immunizations fail. Story | Follow @FierceBiotech

@JohnCFierce: So EU doesn't like Pfizer's Xeljanz at all. That's a blow. More | Follow @JohnCFierce

@RyanMFierce: Industry Voices: Time to Take Fecal Transplantation Seriously. Article | Follow @RyanMFierce

> Biotech startup hustles new Alzheimer's program to the clinic. News

> Johnson & Johnson, Evotec bask in Harvard's breaking diabetes discovery. Article

> Biotech Receptos trots out terms for $71M IPO. Item

> Theravance to split into two biotech groups as GSK drugs progress. More

And Finally... A Novartis ($NVS) plant in Switzerland that makes OTC products that had been slated for closure will now be expanded. Story

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.